Sweden's Orexo Q1 revenue drops, net loss widens

Orexo AB

28/04/2026 06:18

Overview

Sweden specialty pharma firm's Q1 net revenue fell sharply after Zubsolv US divestment

Q1 net loss widened, with EPS at SEK -3.00 versus SEK -2.63 last year

Company increased R&D investment, focusing on AmorphOX and pipeline progress

Outlook

Company plans NDA resubmission for Izipry to FDA in Q3 2026

Orexo expects to start pivotal clinical studies for OX640 in Q4 2026

Company anticipates data read-out for OX390 in Q2 2026

Result Drivers

PIPELINE ADVANCEMENT - Co increased R&D investment, advancing AmorphOX-based programs and preparing pivotal studies for OX640 and OX390

Company press release: ID:nMFNVgM35

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Meet
SEK 5 mln
SEK 5 mln (1 Analyst)
Q1 Adjusted EPS
-SEK 3
Q1 EPS
-SEK 3
Q1 EBIT
-SEK 75 mln
Q1 EBITDA
-SEK 66.10 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Orexo AB is SEK44.00, about 120.9% above its April 27 closing price of SEK19.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)